Similar articles

• AAA- a further step towards a moratorium for aspirin in the primary prevention.

  Minar E. Minar E. Vasa. 2010 May;39(2):119-122. doi: 10.1024/0301-1526/a000016. Vasa. 2010. PMID: 20521434 No abstract available.
• Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.

  Godley RW, Hernandez-Vila E. Godley RW, et al. Tex Heart Inst J. 2016 Aug 1;43(4):318-9. doi: 10.14503/THIJ-16-5807. eCollection 2016 Aug. Tex Heart Inst J. 2016. PMID: 27547141 Free PMC article. No abstract available.
• What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?

  Tousoulis D. Tousoulis D. Cardiovasc Res. 2019 Feb 1;115(2):e15-e16. doi: 10.1093/cvr/cvy281. Cardiovasc Res. 2019. PMID: 30668678 No abstract available.
• Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.

  Volpe M, Battistoni A, Gallo G, Coluccia R, De Caterina R. Volpe M, et al. High Blood Press Cardiovasc Prev. 2017 Sep;24(3):331-339. doi: 10.1007/s40292-017-0213-4. Epub 2017 Jun 1. High Blood Press Cardiovasc Prev. 2017. PMID: 28573479 Review.
• Aspirin for primary prevention: do potential benefits outweigh the risks?

  Shakib S. Shakib S. Intern Med J. 2009 Jun;39(6):401-7. doi: 10.1111/j.1445-5994.2008.01888.x. Intern Med J. 2009. PMID: 19580619 Review.